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The Nottingham Prognostic Index Plus (NPI+) is a clinical decision making tool in breast 
cancer (BC) that aims to provide improved patient outcome stratification superior to the 
traditional NPI. This study aimed to validate the NPI+ in an independent series of BC.  
885 primary early stage BC cases from Edinburgh were semi-quantitatively assessed for 10 
biomarkers [Estrogen Receptor (ER), Progesterone Receptor (PgR), cytokeratin (CK) 5/6, 
CK7/8, epidermal growth factor receptor (EGFR), HER2, HER3, HER4, p53, and Mucin 1] 
using immunohistochemistry and classified into biological classes by fuzzy logic-derived 
algorithms previously developed in the Nottingham series. Subsequently, NPI+ Prognostic 
Groups (PGs) were assigned for each class using bespoke NPI-like formulae, previously 
developed in each NPI+ biological class of the Nottingham series, utilising clinicopathological 
parameters: number of positive nodes, pathological tumour size, stage, tubule formation, 
nuclear pleomorphism and mitotic counts.  Biological classes and PGs were compared 
between the Edinburgh and Nottingham series using Cramer’s V and their role in patient 
outcome prediction using Kaplan–Meier curves and tested using Log Rank.  
The NPI+ biomarker panel classified the Edinburgh series into seven biological classes similar 
to the Nottingham series (p>0.01). The biological classes were significantly associated with 
patient outcome (p<0.001). PGs were comparable in predicting patient outcome between 
series in Luminal A, Basal p53 altered, HER2+/ER+ tumours (p>0.01). The good PGs were 
similarly validated in Luminal B, Basal p53 normal, HER2+/ER- tumours and the poor PG in 
the Luminal N class (p>0.01). Due to small patient numbers assigned to the remaining PGs, 
Luminal N, Luminal B, Basal p53 normal and HER2+/ER- classes could not be validated.   
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This study demonstrates the reproducibility of NPI+ and confirmed its prognostic value in an 
independent cohort of primary breast cancer. Further validation in large randomised 
controlled trial material is warranted.  
 
 
Keywords: breast cancer; classification; prognostic index; molecular; clinical; outcome  
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Breast cancer (BC), is one of the leading causes of death in women but it represents a very 
heterogeneous group of tumours in terms of genotype, phenotype, behaviour and response 
to treatment. With the number of available treatment options, making the most 
appropriate treatment choice is increasingly difficult and complex and therefore a more 
personalised management of BC is required. However, clinical decision making in 
personalised BC treatment requires robust and accurate risk stratification based on 
outcome prediction and biology [1].    
 
Personalised treatment plans for BC require integration of clinical, histopathological and 
biological information to effectively stratify patients with regard to their expected outcome 
and response to the various applicable treatment options.  There has been increasing 
interest in use of multigene assays, such as Oncotype DX® [2] and MammaPrint® [3], and 
their potential clinical utility in BC management.  However, the incorporation of molecular 
taxonomy of BC using gene expression profiling into routine clinical decision-making has not 
proved entirely successful due to factors including reproducibility, validation, cost, and lack 
of utility for all BC patients. 
 
The current Nottingham Prognostic Index (NPI) [4-6] is based on a combination of 
histopathological factors (tumour size, lymph node stage and tumour grading) integrated in 
a prognostic index formula [7] which can be used to stratify BC patients with operable early-
stage primary breast cancer into prognostic groups. The utility of the NPI has been 
confirmed after long-term follow-up [4], validated independently in large multi-centre 
studies [5,8,9], revised in order to stratify patients into additional prognostic groups [10], 
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and is currently adopted in clinical practice in the UK and other parts of Europe and 
Australia. However, the NPI does not reflect the biological heterogeneity of BC and assigns 
equal weighting of the prognostic factors histological grade, tumour lymph node stage and 
tumour size to all cancers.  It therefore requires further enhancement to support more 
accurate personalised management of BC patients.  
 
It is now recognised that the biological characteristics of BC are important for clinical 
management and addition of biological markers to the NPI can significantly improve risk 
stratification of BC patients [11] . We have therefore developed the Nottingham Prognostic 
Index Plus (NPI+ ) [11] which conceptually evolved to modernise the historical NPI by 
applying the prognostic methods used in the NPI, which are based on well-established 
powerful clinicopathological variables, following breast cancer molecular class assignment. 
NPI+ is thus based on a two tier evaluation; the initial assessment determines the biological 
class of the tumour (see below) and is subsequently followed by classification using  
traditional clinicopathological prognostic variables using a  tailored (bespoke) NPI-like 
prognostic formulae for each biological class [11-14]. NPI+ uses routine clinical samples and 
commonplace laboratory methods and could integrate easily into current international 
clinical practice.  It has potential clinical utility by providing improved patient outcome 
stratification and by providing a decision making tool which can identify patients likely to 
have a good outcome following conventional breast cancer treatment and a subgroup(s) of 
patients at risk of adverse outcome i.e. who are at increased risk of treatment failure and 
who could potentially benefit from additional / alternative therapy, should these currently 
be available or become available in the future [11]. Seven core breast cancer NPI+ Biological 
Classes are initially determined by the evaluation of 10 BC-related biomarkers using 
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immunohistochemistry and a fuzzy rule induction algorithm [15] to classify the breast 
tumours. The molecular classes identified based on the combination of these 10 biomarkers 
using fuzzy logic are similar in biomarker profile to those intrinsic classes identified using 
gene expression profiling and include three luminal classes (Luminal A, N and B), two basal 
classes (Basal – p53 altered and Basal – p53 normal) and two HER2+ classes (HER2+/ER+ and 
HER2+/ER-) [15]. These distinct biological classes of BC showed significant association with 
patient outcome [12-14]. Each NPI+ Biological Class is subsequently stratified using a set of 
well-defined prognostic clinicopathological variables which are combined in bespoke 
formulae to stratify each individual NPI+ Biological Class into two or more  prognostic 
subgroups (NPI+ Prognostic Groups) which have been been shown to be superior to the 
classic NPI [11]. 
 
In this study, we aimed to validate the NPI+ in a large independent series of clinically 
annotated early-stage breast cancers from a single centre (Edinburgh, UK) in order to assess 
the potential of NPI+ as a prognostic tool in breast cancer. 
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Materials and methods 
Nottingham series 
A series of 1,073 patients from the Nottingham-Tenovus Primary Breast Carcinoma Series, 
aged 70 years or less, presenting with primary operable (stages I, II and IIIa) invasive breast 
cancer between 1986-98 were previously used to develop the NPI+ [11-14]. This is a well-
characterised consecutive series of patients who were uniformly treated according to 
locally-agreed clinical protocols [12,16]. All tumours were less than 5cm diameter on 
clinical/pre-operative measurement and/or on operative histology (T1 and T2).  Women 
aged over 70 years were not included because of the increased confounding factor of death 
from other causes and because primary treatment protocols for these patients often 
differed from those for younger women. Adjuvant systemic therapies were offered 
according to the Nottingham Prognostic Index (NPI) [2] and hormone receptor (HR) status 
[2][10]. Patients in the Moderate I group (NPI 3.41-4.4) with HR-positive tumours were 
offered hormonal therapy. Patients in the Moderate II (NPI 4.41-5.4) and Poor (NPI >= 5.41) 
groups received hormone therapy for HR-positive tumours and cytotoxic therapy (classical 
cyclophosphamide, methotrexate and 5-fluorouracil (CMF)) for HR-negative tumours if the 
patient was fit enough to tolerate chemotherapy. Hormonal therapy was given to 396 
patients (40.3%) and chemotherapy to 192 (18.9%). A total of 19 patients (1.9%) in the 
Moderate II or Poor prognostic groups received a combination of chemotherapy and 
endocrine therapy (Table 1). Data relating to survival were collated in a prospective manner 
for those patients presenting after 1989 only.  
 
Edinburgh series 
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The Edinburgh series comprised a cohort of 885 patients treated by breast conservation 
surgery, axillary node sampling or clearance, and whole breast radiotherapy between 1981-
98 in Edinburgh (Edinburgh Breast Conservation Series) [17]. Patients were those considered 
suitable for breast-conserving therapy and were T1 or T2, N0 or N1 and M0 for conventional 
tumour node metastasis staging. Patients with larger primary tumours and those with 
multifocal cancers on preoperative assessment were not considered eligible for inclusion. 
Standard surgical treatment was wide local excision. Patients with tumours measuring >2 
cm in diameter and/or clinically N1 received a Level III axillary clearance. For tumours 
measuring clinically ≤2 cm a lower axillary node sample (minimum four nodes) was 
undertaken. Postoperative breast radiotherapy was given at a dose of 45 Gy in 20 daily 
fractions in patients with one or more pathologically involved node on an axillary node 
sample; the peripheral lymphatics were also irradiated over 4 weeks. Patients received 
adjuvant systemic therapy as follows: endocrine therapy (primarily using tamoxifen), 
chemotherapy alone (primarily using CMF), chemotherapy plus endocrine therapy or no 
adjuvant systemic therapy (primarily those with grade 1 tumours).   
 
Breast cancer specific survival (BCSS) is defined as the interval between the operation and 
death from breast cancer, death being scored as an event, and patients who died from 
other causes or were still alive were censored at the time of last follow-up.  
 
This study was approved by the Nottingham Research Ethics Committee 2 under the title 
`Development of a molecular genetic classification of breast cancer'.  
Page 10 of 28The Journal of Pathology: Clinical Research
This article is protected by copyright. All rights reserved.
10 
 
Determination of NPI+ Biological Class 
Immunohistochemical reactivity for the NPI+ biomarkers in the Nottingham series was 
previously determined using standard immunohistochemical techniques on tumour samples 
prepared as tissue microarrays (TMAs) [12]. TMAs for both cohorts were prepared using 
0.6mm cores. For the Nottingham series, one TMA core from the centre and one from the 
periphery of the most representative areas of tumour were included [12]. For the Edinburgh 
series, one TMA core per patient from representative tumour areas was used [18]. The NPI+ 
was developed using the following biomarkers: Estrogen Receptor (ER), Progesterone 
Receptor (PgR), cytokeratin (CK) 5/6, CK7/8 (using the anti-cytokeratin CAM5.2 clone), 
epidermal growth factor receptor (EGFR; HER1), c-erbB2 (HER2), c-erbB3 (HER3), c-erbB4 
(HER4), p53, and Mucin 1 [14]. TMAs of the Edinburgh series were also stained for these 
same biomarkers in Nottingham using the same procedures as previously described 
(Supplementary Table 1) [12,14]. A series of BC, prepared as TMAs, with differing levels of 
expression of the 10 biomarkers (ranging from negative to strongly positive) were included 
as positive and negative controls and to standardise immunoreactivity. Levels of 
immunohistochemical reactivity were determined by microscopic analysis using the 
modified Histochemical score (H-score), giving a semi-quantitative assessment of both the 
intensity of staining (0-3) and the percentage of positive cells (0-100) (multiplied to give 
values between 0-300) [19,20]. Immunohistochemical staining and subsequent scoring, 
conducted by at least two independent scorers, was performed in the Nottingham 
laboratory.  For HER2, the American Society of Clinical Oncology/College of American 
Pathologists Guidelines Recommendations for HER2 Testing in Breast Cancer were used for 
assessment [21]. In the Nottingham series, equivocal (2+) HER2+ cases were confirmed by 
chromogenic in situ hybridisation (CISH) as previously described [22]. The Reporting 
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Recommendations for Tumour Marker Prognostic Studies (REMARK) criteria, recommended 
by [23], were followed. In the Edinburgh series, equivocal cases (n=67) were excluded from 
analysis.  
 For biological classification, a fuzzy logic rule-based method algorithm was used where the 
cut-offs for each biomarker were previously determined [15]. In particular, the median value 
of markers was used for ER, PgR, CK7/8, HER3, HER4 and MUC1. The expertise values were 
used for those markers that had a median equal to zero and for those where clinicians were 
sure about the value to consider (CK5/6, EGFR, p53 and HER2).. Pathological characteristics 
of the 885 cases, along with the Nottingham cases, are summarised in Table 1. Hormonal 
therapy was given to 581 patients (65.6%), chemotherapy to 118 (13.3%) and 91 patients 
(10.3%) received a combination of chemotherapy and endocrine therapy (Table 1).  
 
Determination of NPI+ Prognostic Groups 
The NPI+ Prognostic Groups were then calculated using bespoke NPI-like formulae, 
previously developed in each NPI+ Biological Class of the Nottingham series, utilising the 
existing available clinicopathological parameters (Table 2)[11]. Briefly, these were 
established by utilisation of the Beta values generated by Cox regression analysis in 
predicting BCSS of the well-established histopathologic prognostic factors. These formulae 
were initially derived from the Biological Classes in Green et al 2013 [14]and were 
subsequently refined using the improved biological classification used in Soria et al 2013 
[15] consisting of: number of positive nodes, nodal ratio, pathological tumour size, stage, 
tubule formation, nuclear pleomorphism and mitotic counts. These were identified as the 
most significant variables in the Nottingham series impacting on survival, according to their 
Beta value in Cox regression indicating the magnitude of the influence of the hazard. The 
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Nottingham series was split into the NPI+ Biological Classes and Cox regression analyses 
were performed independently for each class to identify the most significant 
clinicopathological prognostic factors and their beta value in the context of the individual 
classes. NPI+ Prognostic Groups for the Edinburgh series were assigned using the categorical 
cutpoints previously derived from the Nottingham series in each of the NPI+ Biological 
Classes [11]. For this purpose, the original pathology assessments on full-face sections for 
the histopathological parameters were utilised. 
 
Statistical analysis 
The association between NPI+ Biological Classes and both histopathological and clinical 
characteristics was assessed using Cramer’s V [24]. Breast cancer-specific survival (BCSS) 
between NPI+ Biological classes and NPI+ Prognostic Groups was determined using Kaplan–
Meier curves and tested using Log Rank. A p<0.01 was considered significant with 
Bonferroni adjustment for multiple testing. 
 
Results 
Clinicopathological parameters of the Edinburgh series 
There were significant differences in the distribution of grade and size (both p<0.001) of the 
breast tumours between the Nottingham and Edinburgh series with a larger proportion of 
the Nottingham series being of larger tumour size, and of higher grade and stage (Table 1). 
The median follow-up for the Nottingham series was 14.3 years and the Edinburgh series 
was 11.4 years. A total of 328 (36.0%) and 179 (20.2%) patients died due to their disease in 
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the Nottingham and Edinburgh series respectively. The Edinburgh series had better BCSS 
(82.1%) over the first 10 year period compared with the Nottingham series (74.7%).  
 
NPI+ Biological Class  
NPI+ Biological Class was determined in the Edinburgh series using the 
immunohistochemical data for the 10 NPI+ Biomarkers: this showed that there was a similar 
distribution between each of the seven NPI+ Biological Classes (Luminal A, Luminal N, 
Luminal B, Basal p53 altered, Basal p53 normal, HER2+/ER+ and HER2+/ER-) compared with 
the Nottingham series (p=0.629, Table 3). A total of 51 cases (5.8%) were not assigned to 
any class compared with 3.5% in the Nottingham series. There were significant associations 
between the clinicopathological parameters of the Edinburgh series and the NPI+ Biological 
Classes which are summarised in Table 4. The NPI+ Biological Classes were significantly 
associated with patient survival where the Luminal and Basal classes had a better BCSS than 
the HER2+ classes (Figure 1).  
 
NPI+ Prognostic Groups 
There were a similar number of NPI+ Prognostic Groups evident in each of the biological 
classes in the Edinburgh series compared with the Nottingham series, however there was a 
significant difference in the distribution of the NPI+ Prognostic Groups between the 
Nottingham and Edinburgh series (Table 5, p<0.001) [11]. Some of the poor NPI+ Prognostic 
Groups were under-represented in the Edinburgh series due to the relatively lower 
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frequency of highly proliferative tumours in the series (Table 1) which may also explain the 
better survival of this series.  
 
Comparison of the BCSS in each of the NPI+ Prognostic Groups between the Nottingham 
and Edinburgh Series showed there were no significant differences in patient outcome in 
the majority of NPI+ Prognostic Groups (Figure 2). Luminal A tumours, which had good 
representation in all three NPI+ Prognostic Groups, showed comparable patient outcome 
between the Edinburgh and Nottingham Series, as did the BCSS of the Basal p53 altered and 
HER2+/ER+ tumours. Certain NPI+ Groups (Luminal N Group 1; Luminal B Group 2; Basal p53 
normal Group 2; HER2+/ER- Group) could not be compared due to being under-represented 
in the Edinburgh series. 
 
Discussion 
We have developed the NPI+ methodology with a view to increasing the information 
available to clinicians and patients to allow them to offer more personalised choices of 
adjuvant therapy in all early-stage forms of BC. NPI+ was developed on a series of over 
1,000 BC cases from a single centre (Nottingham, UK) with long term follow-up  [11-14].  We 
have previously demonstrated proof-of-principle evidence of its clinical relevance [11-14]. 
We have therefore sought to validate and confirm the prognostic capabilities of NPI+ in a 
large independent series of BC from a separate centre (Edinburgh, UK).  
 
Although there was some difference in the overall distribution of size, stage and grade of 
tumours between the Nottingham and Edinburgh series, the distribution of the NPI+ 
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Biological Classes (Luminal A, Luminal N, Luminal B, Basal p53 altered, Basal p53 normal, 
HER2+/ER+, HER2+/ER-) was similar. This is consistent with the proportion of cancer 
subtypes reported in other studies [3,12,14,25-32], and provides evidence that the 
classification of BC into seven biological classes using a discrete panel of 10 proteins 
assessed by immunohistochemistry is similar between series. 
 
The second evaluation phase of NPI+ uses well-established powerful clinicopathological 
variables to stratify each of the NPI+ Biological Classes into clinically distinct subgroups 
(NPI+ Prognostic Groups) using bespoke NPI-like formulae. In all classes a patient group with 
a better long term outcome was identified which would align with clinical expectation after 
use of appropriate adjuvant therapy. In the Nottingham series in all seven classes one or 
more subgroups of patients were identified who had an adverse long term outcome. These 
latter group(s) of patients are potential candidates for additional / alternative forms of 
therapy as conventional breast cancer management has failed to mitigate against higher 
than expected risk of tumour relapse and death from BC. It is envisaged that NPI+ can 
stratify patients with breast cancers of any biological class type into a category of expected 
good outcome following conventional therapy, or one or more categories of adverse 
outcome following conventional therapy. We fully appreciate that the NPI+ has been 
developed and validated on archival breast material from patients treated historically in 
routine practice with either chemotherapy and/or hormone therapy and does not include 
more contemporary treatments such as trastuzumab. Further validation of NPI+ in key 
breast cancer randomised clinical trials will allow the prediction of disease recurrence under 
these certain treatment options. 
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In the Edinburgh series, the NPI+ Prognostic Groups showed comparable BCSS in the 
Edinburgh series when compared with the Nottingham series in NPI+ Biological Classes:  
Luminal A, Basal p53 altered and HER2+/ER+. The NPI+ Prognostic Groups with a better 
outcome were similarly validated in the NPI+ Biological Classes: Luminal B, Basal p53 normal 
and HER2+/ER- along with the poor NPI+ Prognostic Group in the Luminal N class. However, 
due to very small numbers of patients assigned in the Edinburgh series, the remaining NPI+ 
Prognostic Groups of biological classes Luminal N, Luminal B, Basal p53 normal and 
HER2+/ER- could not be validated.   
  
In conclusion this study shows that the distribution of the NPI+ Biological Classes are similar 
in an independent series of primary BC and we can conclude that biological class 
determination using the NPI+ biomarker methodology is robust between patient series.  We 
observed similar patterns of patient outcome in the majority of NPI+ Prognostic Groups 
between the Nottingham and Edinburgh series and can conclude that NPI+ prognostic 
classification for these groups (all groups of classes Luminal A, Basal p53 altered and 
HER2+/ER+, the good NPI+ Prognostic Groups of classes Luminal B, Basal p53 normal and 
HER2+/ER- and the poor NPI+ Prognostic Group of the Luminal N class) appears 
reproducible. Three of the poor prognostic groups (Luminal N, Luminal B, Basal p53 normal 
and HER2+/ER-) were under-represented in the Edinburgh series due to a lower frequency 
of higher grade tumours and could not be validated in this study. 
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Table 1. Pathological characteristics of the Nottingham and Edinburgh series 
 








1 158 (14.7) 194 (22.0)  
2 348 (32.4) 359 (40.8) <0.001 
3 567 (52.8) 327 (37.2)  
Tubule formation 
1 53 (5.0) 73 (8.3)  
2 346 (33.0) 222 (25.3) 0.002 
3 651 (62.0) 582 (66.4)  
Pleomorphism 
1 19 (1.8) 3 (0.3)  
2 378 (36.1) 346 (39.5) 0.121 
3 651 (62.1) 528 (60.2)  
Mitosis 
1 349 (33.2) 523 (59.6)  
2 190 (18.1) 138 (15.7) <0.001 
3 511 (47.6) 216 (24.6)  
Size 
 0.13 – 10 cm 
(median 2.0 cm) 
0.4 - 7.0 cm 
(median 1.7 cm) 
 
<1.5cm 240 (22.4) 285 (33.6) <0.001 
≥1.5cm 833 (77.6) 564 (66.4)  
Stage 
1 654 (61.0) 614 (69.4)  
2 330 (30.8) 211 (23.8) 0.014 
3 88 (8.2) 60 (6.8)  
Nottingham Prognostic Index 
Excellent 110 (10.3) 137 (15.5)  
Good 200 (18.6) 251 (28.4)  
Moderate 1 293 (27.3) 248 (28.0)  
Moderate 2 277 (25.8) 178 (20.1) <0.001 
Poor 140 (13.0) 53 (6.0)  
Very poor 45 (4.2) 17 (1.9)  
Treatment 
None 410 (40.3) 95 (10.7)  
Chemotherapy 192 (18.9) 118 (13.3) <0.001 
Endocrine Therapy 396 (38.9) 581 (65.6)  
Chemotherapy/Endocrine 
Therapy 
19 (1.9) 91 (10.3)  
Survival 
 0.4 – 25.7 years 
(median 14.3 years) 




Alive 582 (54.2) 584 (66.0)  
Breast cancer specific 
deaths 
328 (30.1) 179 (20.2) <0.001 
Non-breast cancer 
related deaths or lost to 
follow-up 
163 (15.2) 122 (13.8)  
Page 21 of 28 The Journal of Pathology: Clinical Research










Table 2. NPI+ formulae for the Biological classes 
 
Class NPI+ formula 
Luminal A (0.8 x Mitosis) + (0.5 x Size) + (1.8 x Nodal ratio*) 
Luminal N (0.8 x Tubules) + (0.6 x Stage) 
Luminal B (0.7 x Mitosis) + (1.0 x Nodal ratio) 
Basal p53 altered (1.4 x Nodal ratio) + (0.4 x Size) 
Basal p53 normal (0.6 x Stage) + (1.8 x Pleomorphism) 
HER2+/ER+ (0.5 x Size) + (0.9 x Stage) 
HER2+/ER- (0.9 x Stage) – (0.6 x Nodal ratio) 
*Number of nodes positive / Total number of nodes 
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Table 3. Distribution of NPI+ biological classes within the Nottingham and Edinburgh series  
 





Luminal A 288 (26.8) 225 (29.3)  
Luminal N 205 (19.1) 152 (19.8)  
Luminal B 186 (17.3) 140 (18.3)  
Basal p53 altered 113 (10.5) 93 (12.1) p=0.629 
Basal p53 normal 96 (8.9) 70 (9.1)  
HER2+/ER+ 62 (5.8) 32 (3.6)  
HER2+/ER- 85 (7.9) 55 (6.2)  
Unclassified 38 (3.5) 51 (5.8)  
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Table 4. Clinicopathological parameters of the NPI+ breast cancer biological classes in the Edinburgh series 
 





































Size         
<15mm 89 (40.6) 67 (46.5) 50 (36.5) 12 (13.3) 18 (28.1) 7 (23.3) 11 (21.2) 0.169 
(<0.001) ≥15mm 130 (59.4) 77 (53.5) 87 (63.5) 78 (86.7) 46 (71.9) 23 (76.7) 41 (78.8) 
Grade         
1 75 (33.6) 47 (30.9) 35 (25.0) 1 (1.1) 3 (4.4) 3 (9.7) 1 (1.8) 0.381 
(<0.001) 2 108 (48.4) 73 (48.0) 72 (51.4) 10 (10.8) 23 (33.8) 8 (25.8) 23 (41.8) 
3 40 (17.9) 32 (21.1) 33 (23.6) 82 (88.2) 42 (61.8) 20 (64.5) 31 (56.4)  
Lymph Node 
stage 
        
1 172 (76.4) 108 (71.1) 100 (71.4) 68 (73.1) 50 (71.4) 15 (46.9) 31 (56.4) 0.169 
(<0.001) 2 44 (19.6) 40 (26.3) 36 (25.7) 18 (19.4) 18 (25.7) 10 (31.2) 15 (27.3) 
3 9 (4.0) 4 (2.6) 4 (2.9) 7 (7.5) 2 (2.9) 7 (21.9) 9 (16.4) 
NPI         
Excellent 55 (24.8) 33 (21.9) 23 (16.4) 0 1 (1.5) 2 (6.2) 0 0.221 
(<0.001) Good 82 (36.9) 54 (35.8) 53 (37.9) 5 (5.4) 15 (22.1) 5 (15.6) 11 (20.0) 
Moderate 1 52 (23.4) 34 (22.5) 37 (26.4) 39 (41.9) 29 (42.6) 7 (21.9) 17 (30.9) 
Moderate 2 22 (9.9) 26 (17.2) 21 (15.0) 37 (39.8) 19 (27.9) 10 (31.2) 16 (29.1) 
Poor 11 (5.0) 4 (2.6) 4 (2.9) 8 (8.6) 4 (5.9) 6 (18.8) 8 (14.5) 
Very poor 0 0 2 (1.4) 4 (4.3) 0 2 (6.2) 3 (5.5) 
Adjuvant 
therapy 
        
Chemotherapy 5 (2.2) 12 (7.9) 4 (2.9) 25 (26.9) 21 (30.0) 6 (18.8) 16 (29.1) 0.230 
(<0.001) Hormone 
therapy 




14 (6.2) 21 (13.8) 11 (7.9) 10 (10.8) 6 (8.6) 4 (12.5) 6 (10.9) 
No therapy 21 (9.3) 19 (12.5) 13 (9.3) 16 (17.2) 11 (15.7) 3 (9.4) 7 (12.7)  
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Table 5. Distribution of the NPI+ Groups in the Nottingham and Edinburgh series 




Luminal A   
1.1 148 (17.9) 160 (21.2) 
1.2 83 (10.0) 53 (7.0) 
1.3 25 (3.0) 9 (1.2) 
Luminal N   
2.1 133 (16.1) 151 (20.0) 
2.2 17 (2.1) 1 (0.1) 
Luminal B   
3.1 77 (9.3) 133 (17.6) 
3.2 58 (7.0) 3 (0.4) 
Basal – p53 altered   
4.1 86 (10.4) 78 (10.3) 
4.2 10 (1.2) 13 (1.7) 
Basal – p53 normal   
5.1 44 (5.3) 2 (0.2) 
5.2 28 (3.4) 68 (9.0) 
HER2+/ER+   
6.1 31 (3.7) 15 (1.8) 
6.2 25 (3.0) 17 (2.1) 
HER2+/ER-   
7.1 55 (6.6) 53 (6.4) 
7.2 8 (1.0) 0 
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Supplementary Table 1. Antibodies used in the NPI+ 
Antibody Supplier Clone Isotype Dilution Antigen 
Retrieval 
Ck5/6 Dako DS/1684 IgG1 1:50 EDTA 
Ck7/8 BD Biosciences CAM5.2 IgG2a 1:1 Citrate 
EGFR Invitrogen/Zymed 31G7 IgG1 1:30 Proteinase K 
ER Dako SP1 IgG 1:150 Citrate 
HER2 Dako Rabbit 
polyclonal 
N/A 1:400 None 
HER3 Leica RTJ1 IgM 1:30 Citrate 
HER4 Thermo Shandon Rabbit 
polyclonal 
N/A 1:100 Citrate 
MUC1 Leica NCL-MUC-1 IgG1 1:750 Citrate 
p53 Leica NCL-p53-
D07 
IgG2b 1:50 Citrate 
PgR Dako PgR636 IgG1 1:125 Citrate 
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Figure 1. Breast cancer-specific survival of the Edinburgh series with respect to NPI+ Biological Classes. 
 
Figure 2. Patient outcome for the NPI+ Prognostic Groups, comparing the Nottingham and 
Edinburgh series. 
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Figure 1. Breast cancer specific survival of the Edinburgh series with respect to NPI+ Biological Classes.  
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Figure 2. Patient outcome with the NPI+ Prognostic Groups comparing between the Nottingham and 
Edinburgh series.  
81x81mm (300 x 300 DPI)  
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